Publication | Closed Access

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

ImmunogeneticsAutoimmune DiseaseImmunologyExperimental Autoimmune EncephalomyelitisPathologyActive Immunoregulator LaquinimodAutoimmunityAutoantibodiesImmunologic DiseaseImmunotherapyMedicine